ALLMedicine™ Hidradenitis Suppurativa Center

Jul 29th, 2021 - Hidradenitis suppurativa (HS), a chronic, recurrent, debilitating skin disease, is characterized by painful, inflammatory, subcutaneous lesions of the axilla, inguinal, and anogenital regions. Overall prevalence of HS is ~1%, and impact of disease...

Jul 28th, 2021 - At 180 Days Hidradenitis Suppurativa Readmission Rate is Comparable to Heart Failure: Analysis of the Nationwide Readmissions Database.|2021|Edigin E,Kaul S,Eseaton PO,Albrecht J,|

Jul 24th, 2021 - The management of hidradenitis suppurativa (HS) flares with intralesional steroids lacks strong scientific evidence but limited data suggest that it may be useful. To assess the clinical and ultrasound responses of HS flares to ultrasound-guided i...

Jul 23rd, 2021 - Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, sinus tract formation and scarring. The relationship between HS and strokes is not well established. To assess this potential assoc...

Jul 23rd, 2021 - Hidradenitis suppurativa (HS) is an inflammatory, potentially scarring disease of the hair follicle, affecting the apocrine gland-bearing skin areas. The major comorbid disorders associated with the occurrence or the aggravation of the disease are...

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Apr 28th, 2020 - This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study with two secukinumab dose regimens in approximately 471 patients with moderate to severe HS. The study consists of: screening (up to 4 weeks) treatment perio...

Apr 28th, 2020 - This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study with two secukinumab dose regimens in approximately 471 patients with moderate to severe HS. The study consists of: screening (up to 4 weeks) treatment perio...

Apr 2nd, 2020 - Hidradenitis suppurativa is a debilitating and mutilating disease and its pathogenesis is still poorly understood. It involves the development of recurrent, painful nodules in intertriginous areas that become inflamed, form abscesses that may rupt...

Mar 20th, 2020 - Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.

Jan 2nd, 2020 - The goal of this study is to get a better understanding of the impact of the skin condition, Hidradenitis Suppurativa, on quality of life function of patients. Patients with HS will be asked questions about demographics including gender, age, and ...

Apr 29th, 2021 - A cohort study of psoriasis patients in Denmark found that a nonmedical switch from brand name adalimumab to adalimumab biosimilars was not associated with drug retention at 1 year. And another study, a small, single-center retrospective study of ...

Mar 24th, 2021 - Among patients who undergo surgery for hidradenitis suppurativa (HS), wide excision and flap-based reconstruction are associated with lower postsurgical recurrence, yet these options should be balanced against potentially higher morbidity of exten...

Mar 23rd, 2021 - Takeaway Atopic eczema, psoriasis and hidradenitis suppurativa were weakly associated with chronic kidney disease (CKD), independent of obesity, cardiovascular morbidity or non-biologic nephrotoxic skin medications. No evidence supporting this ass...

Mar 15th, 2021 - A wide variety of medications exists for treating hyperhidrosis, a dermatologist told colleagues, but before prescribing anything to a pediatric patient, he recommended, ask the patient a simple question: "What bothers you the most?" The answer wi...

Feb 3rd, 2021 - Delaying surgical reconstruction of fistula structures until after patients with hidradenitis suppurativa (HS) have been on adalimumab for a minimum of 6 months transforms primary wound closure into a highly attractive option, a pilot study sugges...